APA (7th ed.) Citation

Lu Li, Shilei Yang, Fengqi Fang, Li Tian, Ying He, Jia Li, . . . Deshi Dong. (2024). The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: A cost-effectiveness analysis in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Lu Li, Shilei Yang, Fengqi Fang, Li Tian, Ying He, Jia Li, Yanwei Chen, and Deshi Dong. The Value of Second-line Anti-HER2 Therapy in Metastatic HER-2 Positive Patients: A Cost-effectiveness Analysis in China. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Lu Li, et al. The Value of Second-line Anti-HER2 Therapy in Metastatic HER-2 Positive Patients: A Cost-effectiveness Analysis in China. Frontiers Media S.A., 2024.